[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-dependent-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-dependent-diabetes":194},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,83,106,132,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100628559","integrating-new-skills-into-diabetes-education-with-cgm-100628559",false,"NCT07463209","Integrating New Skills Into Diabetes Education With CGM","Integrating New Skills Into Diabetes Education With CGM (INSIDE-CGM): An Individualized CGM Integration Program for Older Adults With Diabetes","INSIDE-CGM","Participant Inclusion Criteria:\n\n* Adults 65 years and older at time of consent\n* Actively receiving care at a UNC Health or UNC Physicians Network clinic (defined as 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics within the past 365 days). Locality for care is defined as residing within a 90-mile radius of UNC Main Hospital on Manning Drive in Chapel Hill, NC.\n* Using any insulin\n* No continuous glucose monitor (CGM) use within the previous 365 days\n* Willing to use a smartphone to access glucose readings using CGM phone app\n* Fluent in English\n\nParticipant Exclusion Criteria:\n\n* Clinical diagnosis of dementia, assessed through chart review and self-report on screening visit (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable)\n* Currently receiving dialysis, assessed through chart review and self-report on screening visit\n* Extreme visual or hearing impairment that would impair ability to use real-time CGM or attend and participate in an in-person or virtual group intervention session, assessed at screening visit\n* The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \\\u003C1 year, assessed at screening visit\n* Unavailable for 6-week study duration (such as planned surgery or procedure, planned vacation, etc.) or unwilling to comply with study procedures\n* Not fluent in English\n* Unable to consent to recording of sessions\n\nCare Partner Inclusion Criteria:\n\n* Live in the same household as the study participant\n* Age 18 years or older\n* Fluent in English\n* Be willing to attend sessions alongside the study participant and learn how they can better support their partner participant to manage diabetes\n* Consent to recording of sessions","ALL","65 Years",{"count":20,"type":21},144,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin. This study will learn if a three-stage CGM integration program (\"intervention\") that includes sessions focused on CGM technology skills, data skills, and lifestyle skills impacts CGM wear-time, glycemic metrics, and participant-reported outcomes, compared to two standard CGM training approaches (\"comparators\").\n\nFollowing a screening visit and baseline data collection, participants will be randomized to either the intervention or one of the two comparator arms for 6 weeks. The intervention involves three educational sessions over 4 weeks. The first session will be in-person and subsequent sessions will be virtual. Participants in the intervention may receive 1-2 additional individualized training sessions to review CGM skills. The first comparator (Comparator A) will receive a one-time clinic-based CGM training. The second comparator (Comparator B) will be provided with a comprehensive informational pamphlet about CGM. All participants will complete outcomes data collection at 6 weeks.\n\nThe study will also explore participant experiences through a series of semi-structured interviews with a subset of purposively selected participants and their care partners to identify opportunities for scaling the intervention to a broader population. An extension phase of the study will evaluate long-term CGM use and associated outcomes 3- and 6-months post-intervention.\n\nLastly, we will run an additional small sub-study where consented care partners of participants will attend the intervention or comparator sessions alongside the study participant and provide care partner-specific data.",[27,28,29,30,31,32,33],"Insulin Dependent Diabetes","Diabetes (DM)","Diabetes (Insulin-requiring, Type 1 or Type 2)","Diabetes Education","Diabetes Care","Type 1 Diabetes (T1D)","Type 2 Diabetes Mellitus (T2DM)",[35,36,37,38,39,30],"Continuous Glucose Monitor","Diabetes","Insulin Dependent","Older Adults (65 years and older)","CGM","NOT_YET_RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-26","ACTUAL",{"date":46,"type":21},"2026-06",{"date":48,"type":21},"2028-06",{"name":50,"class":51},"University of North Carolina, Chapel Hill","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100642748","mathematical-modeling-of-blood-sugar-and-hormone-responses-in-insulin-dependent-type-2-diabetes-100642748","NCT07650682","Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes","Mathematical Modeling of Type 2 Diabetes Mellitus","MT2D","Inclusion Criteria:\n\n* Men or women, 18-65 years of age\n* Diagnosed with insulin-dependent type 2 diabetes mellitus HbA1c ≥ 6.5% at screening\n* Current insulin therapy for ≥ 6 months prior to screening\n* Nonsmokers (past smokers can be allowed if they have abstained for a minimum of 12 months)\n* Judged to be in good health based on medical history (i.e., no clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal, or hepatic disease)\n* Able to provide informed consent\n* Able to comply with and perform the procedures requested by the protocol (including dietary restrictions, consumption of study foods, records of food diary, sample collection procedures, and study visit schedule)\n\nExclusion Criteria:\n\n* Men and women with known or suspected intolerance, allergies, or hypersensitivity to study foods\n* Men and women with low hemoglobin (Hgb) levels below 9.5 g\u002FdL at the screening visit, indicating anemia\n* Men and women with blood pressure \\>160 mmHg (systolic) \u002F 100 mmHg (diastolic) at the screening visit\n* Women who are pregnant or planning to become pregnant during the study\n* Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI.\n* Vegan or other extreme dietary regimens (e.g., Atkins diet, etc.) as judged by the investigator\n* History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional\n* Donated blood within the last 3 months\n* Unstable weight: gained or lost weight +\u002F- 5 kg (11 lbs) in previous 2 months\n* Unusual working hours i.e., working overnight (e.g. 3rd shift)","18 Years",{"count":63,"type":21},25,"OBSERVATIONAL","This observational study aims to collect detailed metabolic and physiologic data from adults with insulin-dependent type 2 diabetes mellitus following consumption of a mixed meal tolerance test. Participants will undergo frequent blood sampling over a 4-hour period after consuming a standardized liquid mixed meal to measure glucose, insulin, glucagon, C-peptide, and triglyceride responses. Participants will also use continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions.\n\nThe purpose of this study is to develop mathematical models and digital representations (\"digital twins\") of people with type 2 diabetes mellitus. These models may help researchers better understand metabolic responses to meals, physical activity, and diabetes treatments, and may support future development of personalized diabetes technologies and therapies.",[67,27],"Type 2 Diabetes",[69,70,71],"Liquid Meal Test","Digital Twin","Continuous Glucose Monitoring","RECRUITING","2026-06-12",{"date":75,"type":44},"2026-06-16",{"date":77,"type":44},"2026-05-20",{"date":79,"type":21},"2027-03-20",{"name":81,"class":82},"Clinical Nutrition Research Center, Illinois Institute of Technology","INDUSTRY",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":52},"100422639","use-of-cgm-in-kidney-transplant-recipients-100422639","NCT04783441","Use of CGM in Kidney Transplant Recipients","Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients","Inclusion Criteria:\n\n1. Age 18 or above\n2. Received a kidney transplant within the past year with functioning kidney (eGFR \\> 30 mL\u002Fmin\n3. Person with Type 2 Diabetes and on insulin\n4. Access to home wi-fi connection\n\nExclusion Criteria:\n\n1. Person with Type 1 Diabetes\n2. Patients taking hydroxyurea\n3. Patient unable to wear the Dexcom G6 device at all times for any reason\n4. Must be able to test blood glucose with meter 4x a day when on blinded CGM.\n5. Presence of clinically significant visual or cognitive impairment\n6. Illiterate\n7. Prisoners\n8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding\n9. Presence of clinically unstable cardiovascular disease\n10. Active malignancy treatment",{"count":91,"type":21},80,[24],"The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg\u002FdL) in the Diabetic Kidney Transplant population.",[95,96,27],"Kidney Transplant; Complications","Diabetes Mellitus, Type 2","2026-01-27",{"date":99,"type":44},"2026-01-29",{"date":101,"type":44},"2021-06-29",{"date":103,"type":21},"2026-12-31",{"name":105,"class":51},"University of California, Davis",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":113,"targetDuration":115,"studyType":64,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":52},"100612259","the-seafarers-continuous-glucose-monitoring-systems-study-100612259","NCT07251257","The Seafarers' Continuous Glucose Monitoring Systems Study","(SeaGM)","Inclusion Criteria:•\n\n* Any ethnicity\n* Seafarers requiring insulin replacement therapy,\n* Holding a valid ML5 or ENG1 certificate\n* Able and willing to wear a Continuous Glucose Monitoring system (GCMS) for 12 months\n* Able and willing to document out of range glucose values and activities in Fishers Watch App a while at sea\n\nExclusion Criteria:\n\n* Outside of the stated age range.\n* Not able to use using a CGM glucose monitoring system for monitoring the glucose levels.",{"count":114,"type":21},50,"12 Months","People with diabetes sometimes consider that they are subjected to unfair discrimination in the occupational or work environment. These include safety-critical activities, such as operating machinery and driving 1-3. Some occupations preclude the use of medications that lower blood glucose, particularly insulin. Safety regulators, occupational health physicians and national organisations frequently have to balance the competing priorities of individual rights against public safety.\n\nModern treatment, with advances in insulin therapy and glucose monitoring, combined with rigorous clinical assessment and review, has allowed stereotypical attitudes to be challenged and advocated individual assessment with respect to safety criteria. Along with the UK Driving and Vehicle Licensing Agency (DVLA) and Civil Aviation Authority (CAA), the Maritime and Coastguard Agency (MCA) have accepted that insulin-treated diabetes should not be an absolute contra-indication to partaking in these occupational activities4. However, as the Disability Discrimination Act (1995) recognises that there may be specific employment-related hazards, fitness to work should be assessed on an individual basis. Therefore, each of these transport agencies has established regulatory standards for their respective domains, with the priority of minimising hypoglycaemic incapacitation risks. The CAA, for example, has worked alongside other European countries to use the ARA.MED.330 protocol and require medically certified pilots to check their blood glucose levels regularly before and during flights. In 2010, the UK CAA's expert committee reviewed the knowledge and policies concerning flying and it was decided that Continuous Glucose Monitoring (CGM) systems were not accurate enough and instead used finger prick-blood glucose monitoring (SMBG) as the gold standard. Since then, the protocol has been successfully implemented and there are current works in progress that demonstrate sufficient accuracy in modern CGMs as a viable alternative to SMBG.\n\nSimilarly, the guidelines devised by the MCA, Approved Doctor's Manual (ADM), place a great emphasis on the type and treatment of diabetes, with the primary concern being risks of cognitive impairment or incapacitation5. Emphasis is placed on the need for able glycaemic control and \"full awareness of impending hypos, with no reported or observed significant hypoglycaemic episodes in the last year\". The guidance stipulates that certification may be restricted on individuals pending their medication side effects, compliance, and vascular risk factor control. Previous regulations prevented seafaring individuals such as insulin-treated seafarers from partaking in lone watchkeeping\u002Flone-working roles and restricted them to near-coastal duties (150-200 nautical miles) (Appendix 1). Current regulations allows for exemptions for certain vessels, provided that the seafarer's diabetes control remains stable and is subject to blood glucose monitoring. Regardless, an approved medical assessor is needed to conduct these specific medical assessments in line with the statutory standards in MSN 1886 and guidance in the ADM.\n\nAll seafarers who are insulin-dependent and licenced to undertake seafaring in the UK will be invited to participate in this study.",[27],[119,120,121,122],"insulin dependent diabetes","Continuous glucose monitoring","Seafarers","Fishers","2026-01-05",{"date":125,"type":44},"2026-01-06",{"date":127,"type":44},"2025-11-20",{"date":129,"type":21},"2027-04-01",{"name":131,"class":51},"University of Surrey",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":61,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":64,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":52},"100566402","commercial-or-open-source-closed-loop-impact-on-pregnancy-study-100566402","NCT06654713","Commercial or Open Source Closed Loop Impact on Pregnancy Study","Commercial or Open Source Closed Loop Impact on Pregnancy (COSCLIP) Study","COSCLIP","Inclusion criteria:\n\n* Pregnant\n* Diagnosis of type 1 diabetes (T1D) prior to pregnancy\n* Active use of automated insulin delivery (AID) system\n\nExclusion criteria:\n\n* Diagnosis of other forms of diabetes (gestational diabetes, type 2 diabetes, monogenic diabetes)","FEMALE",{"count":142,"type":21},1000,"1 Year","The goal of this observational study is to better understand what happens when pregnant people with type 1 diabetes (T1D) use automated insulin delivery (AID) systems. The main questions this study aims to answer are:\n\n* What are the maternal and neonatal outcomes with AID system use in pregnancy?\n* What are the glycemic outcomes with AID system use in pregnancy?\n* What are the behavioral and emotional outcomes with AID system use in pregnancy?\n\nResearchers will compare pregnant people who use commercial AID systems and pregnant people who use open source AID systems to see if outcomes are different with these different types of systems.\n\nParticipants will be asked to remotely share their AID system data with the research team; complete online surveys regarding behavioral and emotional health; and sign an authorization to release health information to allow the research team to access medical records.",[146,147,27,148],"Type 1 Diabetes","Pregnancy, High Risk","Pregnancy Related","2025-05-06",{"date":151,"type":44},"2025-05-07",{"date":153,"type":44},"2025-03-13",{"date":155,"type":21},"2029-12-31",{"name":157,"class":51},"University of California, San Francisco",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":140,"minAge":61,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100589815","t1d-pregnancy--me-100589815","NCT06959316","T1D Pregnancy & Me","Pregnancy Data Repository to Assess Management of Type 1 Diabetes With Diabetes Technology","PRAM-T1D","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Clinical diagnosis of presumed T1D for at least 6 months duration\n3. Less than 15 weeks gestation at time of enrollment based on due date from provider\n4. Planned CGM use on a regular basis (e.g., ≥10 out of 14 days) and willing to continue using CGM regularly with no plans to discontinue CGM use during the study\n5. Following intensive insulin therapy regimen defined as basal-bolus delivery via an insulin pump (including a closed loop system) or multiple daily injections (MDI)\n6. Have access to technology that may be required to complete study questionnaires and share diabetes device data.\n7. Resident of the United States and plans to reside in the U.S. for the duration of the study\n8. Comprehends written and spoken English or Spanish\n9. Willing and able to provide informed consent, complete surveys and provide the device data that are part of the protocol\n\nExclusion Criteria:\n\n1. Multiple pregnancy\n2. Current renal dialysis or plan to begin renal dialysis during the study\n3. History of liver cirrhosis\n4. Active cancer treatment with systemic chemotherapy\n5. Current participation in other studies involving an investigational insulin delivery device or planning to participate in an investigational insulin delivery device study during pregnancy\n6. Prior participation in this study",{"count":167,"type":21},500,"T1D Pregnancy \\& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.",[170,171,172,27],"Diabetes Mellitus, Type 1","Pregnancy in Diabetics","Pregnancy, High-Risk",[174,175,176,177,178,179,180,181,39,182,183,184],"Type 1 diabetes","Pregnant","Pregnancy","Insulin pump","Continuous glucose monitor","Remote study","Online study","T1D","Insulin injection","Hybrid closed loop","HCL","2025-04-28",{"date":149,"type":44},{"date":188,"type":44},"2025-04-25",{"date":190,"type":21},"2027-04",{"name":192,"class":51},"Jaeb Center for Health Research",10,"Insulin-dependent Diabetes"]